Keumyoung Ahn

6PUBLICATIONS
62CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular medicineModels of care and place of birthNanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 02, 2026
Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer.

|Apr 26, 2024
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.

Min Ho Park, Jae Hong Seo, Jung Ho Park

|Oct 13, 2023
Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea.

Ji Yeon Lee, Seon Hee Bu, EunHyang Song

|Mar 07, 2023
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.

Justin Stebbing, Yauheni Baranau, Valery Baryash

|Feb 09, 2023
A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.

Jae-Cheol Jo, Youngwoo Jeon, DaJung Kim

|Aug 25, 2022
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Ji-Min Seo, Bobin Kang, Rina Song

Pageof 1

Frequent Collaborators

4 joint publications

TaeHong Park

3 joint publications

Hyungseok Baek

2 joint publications

Sunghyun Kim

2 joint publications

Hana Ju